Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07011823 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC

Study acronym: KEY-MELT
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
A single-arm, single-institution study to induce phenotypic changes in the tumor microenvironment by delivering 8Gy partial breast irradiation in immune-cold triple-negative breast cancer confirmed by PD-L1 and TILs. Additional tissue biopsy will be performed following radiation therapy. Subsequently, neoadjuvant chemotherapy including Pembrolizumab will be administered to evaluate whether pathological complete response rates are improved.
Trial Details
NCT Number NCT07011823
Lead Sponsor Gangnam Severance Hospital
Conditions
(from sponsor)		 Triple-Negative Breast Neoplasm
Related terms Triple Negative Breast Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov